Drug Trial Radar · NCT04606264
Recommendations of Enhanced Recovery Interventions for Patient's Clinical Team and Collection of Associated Data
Last checked: Nov 19, 2026Latest source record: May 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,395
Actual
Start
May 15, 2023
Primary completion
Mar 21, 2025
Study completion Mar 21, 2025
Sponsor
- Lead sponsor
- Jennifer Holder-MurrayAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Berry Consultants
- First posted
- Oct 28, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This REMAP Periop ERP domain study falls under the Periop Core Protocol, which compares the different recommended strategies for enhancing recovery through the use of various standard of care treatments before, during and after surgery in all patients with elective surgical encounters at UPMC who meet eligibility criteria. The ERP domain seeks to enhance recovery by optimizing strategies of perioperative care through evaluating combinations of perioperative treatment, which consists of preoperative, intraoperative and postoperative care. Optimal combinations of perioperative care will be generated and analyzed to determine the best outcomes for patients as defined by reduction in hospital free days, reduction in postoperative nausea and vomiting, and improved pain control.
Conditions
- Perioperative Optimization
Interventions
Neuraxial AnalgesiaDrug
This randomized group will receive a neuraxial morphine injection (intrathecal morphine/hydromorphone).
Regional Block 1: ParavertebralDrug
This randomized group will receive regional technique analgesia with sodium channel nerve blockade pharmacotherapy (ie nerve block)
PerphenazineDrug
This randomized group will receive 8 mg of perphenazine orally preoperatively.
AprepitantDrug
This randomized group will receive 40 mg of aprepitant orally preoperatively.
DimenhydrinateDrug
This randomized group will receive 25 mg of dimenhydrinate orally preoperatively.
Ondansetron 4 MGDrug
This randomized group will receive 4 mg of ondansetron orally.
DexamethasoneDrug
This randomized group will receive 4-5 mg of dexamethasone intravenously.
Regional Block 2: QL1Drug
This randomized group will receive regional technique analgesia with sodium channel nerve blockade pharmacotherapy (ie nerve block)
Primary outcomes
What the sponsor says the trial is designed to measure.
- 30 Day Hospital Free DaysTime frame: Day 0 - Day 30
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
UPMC Magee-Womens Hospital
Pittsburgh, Pennsylvania
UPMC Presbyterian
Pittsburgh, Pennsylvania
UPMC Passavant
Pittsburgh, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.